Characteristics | IIT Public Germany gov No. of trials (%) | IIT Public Germany other No. of trials (%) | IIT Public Germany (total) No. of trials (%) | IIT Public International No. of trials (%) | IST Commercial Germany No. of trials (%) | IST Commercial International No. of trials (%) | Total No. of trials (%) |
---|---|---|---|---|---|---|---|
Total | 60 | 60 | 120 (100) | 200 (100) | 171 (100) | 200 (100) | 691 (100) |
Registered ina | |||||||
ClinicalTrials.gov | 32 (53) | 16 (27) | 48 (40) | 200 (100) | 158 (92) | 200 (100) | 606 (88) |
DRKSb | 14 (23) | 48 (80) | 62 (52) | – | 19 (11) | – | 81 (12) |
ISRCTNc | 27 (45) | 5 (8) | 32 (27) | 3 (1) | – | – | 35 (5) |
EudraCTd | 40 (67) | 10 (17) | 50 (42) | 18 (9) | 88 (52) | 33 (17) | 189 (27) |
Study status | |||||||
Completed | 43 (72) | 59 (98) | 102 (85) | 200 (100) | 170 (100) | 200 (100) | 672 (97) |
Prematurely ended | 12 (20) | 1 (2) | 13 (11) | 1 (< 1) | 14 (2) | ||
Still ongoinge | 5 (8) | – | 5 (4) | 5 (< 1) | |||
Collaboration | |||||||
International | 19 (32) | 7 (12) | 26 (22) | 44 (22) | 71 (42) | 69 (35) | 210 (30) |
National | 40 (66) | 53 (88) | 93 (78) | 156 (78) | 100 (58) | 131 (65) | 479 (69) |
Unclear | 1 (2) | – | 1 (< 1) | – | – | – | 2 (< 1) |
Study size (Median = 150) | |||||||
> 150 | 46 (76) | 28 (47) | 74 (62) | 81 (40) | 74 (43) | 115 (58) | 344 (50) |
≤ 150 | 13 (22) | 32 (53) | 45 (38) | 119 (60) | 97 (57) | 85 (42) | 346 (50) |
Unclear | 1 (2) | – | 1 (< 1) | – | – | – | 1 (< 1) |
Number of primary outcome(s) | |||||||
0 | – | – | – | – | 1 (1) | – | 1 (< 1) |
1 | 44 (73) | 44 (73) | 88 (73) | 152 (76) | 122 (71) | 133 (67) | 495 (72) |
> 1 (range 2–36) | 16 (27) | 16 (27) | 32 (27) | 48 (24) | 48 (28) | 67 (33) | 195 (28) |
Study phase drug trialsf | |||||||
Total | 41 (68) | 15 (25) | 56 (47) | 93 (47) | 93 (54) | 93 (47) | 335 (48) |
2 | 9 (15) | 5 (8) | 14 (12) | 23 (12) | 23 (13) | 23 (12) | 83 (12) |
3 | 20 (33) | 7 (12) | 27 (22) | 45 (23) | 45 (26) | 45 (23) | 162 (23) |
4 | 12 (20) | 3 (5) | 15 (13) | 25 (13) | 25 (15) | 25 (13) | 90 (13) |
Study phase non-drug trialsg | |||||||
Total | 19 (32) | 45 (75) | 64 (53) | 107 (53) | 78 (46) | 107 (53) | 356 (52) |
A | – | 9 (15) | 9 (7) | 15 (7) | 11 (7) | 15 (7) | 50 (7) |
B | 16 (27) | 33 (55) | 49 (41) | 82 (41) | 43 (25) | 82 (41) | 256 (37) |
C | 3 (5) | 3 (5) | 6 (5) | 10 (5) | 24 (14) | 10 (5) | 50 (7) |